InMed Pharmaceuticals (INM) Operating Leases (2020 - 2026)
InMed Pharmaceuticals' (INM) quarterly Operating Leases came in at $30766.0 in Q1 2026, down 92.66% year-on-year from $419347.0 in Q1 2025, and down 75.15% quarter-over-quarter from $123827.0 in Q4 2025.
InMed Pharmaceuticals (INM) Operating Leases (2020 - 2026) Analysis & Trends
InMed Pharmaceuticals' Operating Leases history runs 7 years deep, the most recent figure standing at $30766.0 for Q1 2026.
- On a quarterly basis, Operating Leases fell 92.66% year-over-year to $30766.0 in Q1 2026; TTM through Mar 2026 was $30766.0, a 92.66% decrease from a year earlier, with the FY2025 full-year figure at $305755.0, down 52.59% from the prior year.
- Operating Leases retreated to $30766.0 in Q1 2026 per INM's latest filing, from $123827.0 in the prior quarter.
- Across five years, Operating Leases topped out at $1.1 million in Q3 2024 and bottomed at $15994.0 in Q2 2023.
- The 5-year median for Operating Leases is $305755.0 (2025), against an average of $388143.2.
- Across the five-year window, Operating Leases sank 95.89% in 2023 and soared 3931.92% in 2024, its largest moves.
- Year by year, Operating Leases stood at $183902.0 in 2022, then jumped by 336.53% to $802784.0 in 2023, then plunged by 34.07% to $529248.0 in 2024, then plunged by 76.6% to $123827.0 in 2025, then slumped by 75.15% to $30766.0 in 2026.
- Per Business Quant, the three latest INM Operating Leases figures stand at $30766.0 (Q1 2026), $123827.0 (Q4 2025), and $215478.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,766.00 |
| Dec 31, 2025 | 123,827.00 |
| Sep 30, 2025 | 215,478.00 |
| Jun 30, 2025 | 305,755.00 |
| Mar 31, 2025 | 419,347.00 |
| Dec 31, 2024 | 529,248.00 |
| Sep 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | 644,865.00 |
| Mar 31, 2024 | 725,236.00 |
| Dec 31, 2023 | 802,784.00 |
| Sep 30, 2023 | 292,998.00 |
| Jun 30, 2023 | 15,994.00 |
| Mar 31, 2023 | 72,794.00 |
| Dec 31, 2022 | 183,902.00 |
| Sep 30, 2022 | 294,337.00 |
| Jun 30, 2022 | 389,498.00 |
| Mar 31, 2022 | 493,562.00 |
| Dec 31, 2021 | 598,642.00 |
| Sep 30, 2021 | 178,591.00 |
| Jun 30, 2021 | -51,108.00 |